Study guide

6.3 Hemophilia, von Willebrand Disease, and Coagulopathies

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

6.3 Hemophilia, von Willebrand Disease, and Coagulopathies

Key Takeaways Explain This Topic AI

Hemophilia A is factor VIII deficiency and hemophilia B is factor IX deficiency; both are X-linked, and severe disease presents with hemarthrosis, iliopsoas bleeds, and intracranial hemorrhage after head trauma.

Replacement includes standard and extended-half-life factor; emicizumab is a factor VIII mimetic for hemophilia A, not B, and breakthrough bleeds still need factor, with thrombosis caution if combining with activated prothrombin complex concentrates.

Desmopressin can raise factor VIII and von Willebrand factor in mild hemophilia A and type 1 von Willebrand disease; watch hyponatremia and restrict free water.

Von Willebrand disease is typed 1 (partial quantitative), 2 (qualitative), and 3 (near-absent); mucosal bleeding dominates, and VWF antigen plus activity (ristocetin-based assays) are the high-level lab concepts.

Head injury: infuse factor first and image in parallel. Counsel sports by bleed risk. Avoid intramuscular injections and NSAIDs generally.

Last updated: August 2026

A toddler who limps after a minor bump, an adolescent with a swollen knee the morning after basketball, and a school-age child who hit a coffee table with his head are the CPHON coagulopathy cases. Hemophilia A, hemophilia B, and von Willebrand disease (vWD) are not interchangeable product problems. The nurse names the missing protein, the bleed pattern, and whether the next syringe is factor, a mimetic, desmopressin, or a von Willebrand-containing concentrate.

Hemophilia A versus B, inheritance, and bleed geography

Hemophilia A is factor VIII deficiency. Hemophilia B is factor IX deficiency. Both are X-linked : males are typically affected; females may be symptomatic carriers if lyonization is skewed. Severity tracks residual factor activity in broad bands: severe disease (typically less than 1%) bleeds spontaneously into joints; moderate disease bleeds with modest trauma; mild disease may present only after surgery or dental work. Do not wait for a family history. About one-third of cases are new mutations.

Hemarthrosis is the signature musculoskeletal bleed. Blood in the joint causes pain, warmth, and loss of motion; repeated bleeds create a target joint and chronic hemophilic arthropathy. Early factor, rest, ice, and staged return to motion beat “walk it off.” Iliopsoas bleeds present as groin or flank pain, hip flexion, and sometimes femoral-nerve symptoms; they can hide a large volume of blood. A 12-year-old with hemophilia A who refuses to straighten the hip after a stumble is not “just a pulled muscle” until factor has gone in and imaging, if needed, is arranged.

Intracranial hemorrhage after head trauma is the life-threatening bleed. In severe hemophilia, even a seemingly minor head bump can seed a subdural or intracerebral hematoma. Mucosal bleeding—epistaxis, gum oozing, heavy menses in carriers or in vWD—is more typical of platelet–von Willebrand physiology than of classic hemophilia, though hemophilia can still bleed from the mouth after dental work.

  • Disorder Missing or defective protein Typical inheritance Classic bleed
  • Hemophilia A Factor VIII X-linked Hemarthrosis, muscle, ICH after trauma
  • Hemophilia B Factor IX X-linked Same geography as A
  • vWD type 1 Partial quantitative VWF Usually autosomal Mucosal, surgical oozing
  • vWD type 2 Qualitative VWF defects Autosomal (subtype-specific) Mucosal; 2B may drop platelets
  • vWD type 3 Near-absent VWF Autosomal recessive Severe, hemophilia-like plus mucosal
  • Replacement: standard, extended half-life, and emicizumab

On-demand or prophylactic factor VIII (hemophilia A) or factor IX (hemophilia B) remains the specific replacement. Extended-half-life products lengthen intervals for prophylaxis; they are still factor, still disease-specific, and still dosed by the hemophilia clinic’s protocol—not by a floor nurse inventing units per kilogram from memory on the exam. Teach venous access, home infusion competence, and that a swollen joint is a treat-now event, not a wait-for-clinic-hours event.

Emicizumab is a bispecific monoclonal antibody that mimics factor VIII function by bridging activated factor IX and factor X. It is subcutaneous prophylaxis for hemophilia A , including many children with inhibitors. It is not a hemophilia B drug . Breakthrough bleeds still need factor VIII (or a bypassing agent per protocol). Combining emicizumab with activated prothrombin complex concentrates (aPCCs) has been associated with thrombosis and thrombotic microangiopathy; teach caution. Many protocols avoid aPCC or restrict it tightly and prefer recombinant factor VIIa for selected breakthrough bleeds on emicizumab. Do not invent a milligram-per-kilogram aPCC cap as an ONCC number; know the interaction is dangerous and that you call the hemophilia center before stacking bypassing agents.

A 4-year-old with severe hemophilia A on weekly emicizumab who wakes with a hot, swollen knee still needs a breakthrough hemostatic plan. Emicizumab prophylaxis is not a reason to withhold factor.

Desmopressin, vWD types, and the ristocetin idea

Desmopressin releases stored factor VIII and von Willebrand factor from endothelium. It can treat mild hemophilia A and type 1 vWD for minor procedures. It does not treat hemophilia B (no factor IX is stored that way) and is not adequate as sole therapy in type 3 vWD , where stores are essentially absent. Tachyphylaxis appears with closely repeated doses. The nursing trap is hyponatremia : restrict free water, avoid hypotonic floods, and watch toddlers who will drink continuously if handed a sippy cup after the dose. A 7-year-old given desmopressin before dental extraction who then drinks liters of water is a seizure risk, not a “well-hydrated” success.

Von Willebrand disease is the most common inherited bleeding disorder. Type 1 is a partial quantitative deficiency. Type 2 is qualitative (2A, 2B, 2M, 2N—recognize that quality, not only quantity, can fail). Type 3 is near-absent VWF and behaves like severe hemophilia plus mucosal bleeding. Labs at the level this exam expects: VWF antigen (how much protein), VWF activity (classically ristocetin cofactor or related GPIb-binding assays—how well it works), and factor VIII (which VWF protects). You do not need to interpret every subtype panel at the bench; you do need to know that “vWD” is not one product order.

Head injury, sports, and what not to inject

Head injury in hemophilia: treat first, image in parallel. Infuse the appropriate factor immediately for significant head trauma or neurologic change. Do not hold factor in the CT queue so that “product is not wasted if the scan is normal.” A normal early scan does not always close observation; a delay to factor can finish the bleed the scanner has not yet shown. A 9-year-old with hemophilia B who struck his head on a table gets factor IX on the way to imaging, not after the radiology report.

Sports counseling is individualized. Swimming, running, and similar lower-impact activities are generally encouraged on prophylaxis. High-impact collision and unsanctioned tackling are discouraged in severe disease. The goal is participation with a bleed plan, not lifelong bubble wrap. School nurses need the product name, the fever-versus-bleed number, and instructions that intramuscular injections and NSAIDs are generally avoided because of hematoma risk and platelet dysfunction. Vaccines are given subcutaneously when possible or with factor cover per the hemophilia clinic. Acetaminophen is the usual first analgesic for mild pain; ketorolac intramuscularly is the wrong reflex.

The CPHON product is a family that can name A versus B, infuse or access prophylaxis, treat a head bump before the scanner, keep water modest after desmopressin, and call before anyone combines emicizumab with an aPCC.

Loading diagram... Hemophilia head trauma and product matching